Cargando…
Biomarker analysis of on-treatment and at progression biopsies from BRIM7 - a phase 1B trial of combined vemurafenib and cobimetinib treatment in BRAF V600 mutated melanoma
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4108918/ http://dx.doi.org/10.1186/1479-5876-12-S1-O12 |
| _version_ | 1782327809807482880 |
|---|---|
| author | Yan, Yibing McArthur, Grant Hamid, Omid Puzanov, Igor Gonzalez, Rene Gajewski, Thomas Wang, Yulei Wongchenko, Matthew Choong, Nicholas Ribas, Antoni |
| author_facet | Yan, Yibing McArthur, Grant Hamid, Omid Puzanov, Igor Gonzalez, Rene Gajewski, Thomas Wang, Yulei Wongchenko, Matthew Choong, Nicholas Ribas, Antoni |
| author_sort | Yan, Yibing |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4108918 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2014 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-41089182014-08-04 Biomarker analysis of on-treatment and at progression biopsies from BRIM7 - a phase 1B trial of combined vemurafenib and cobimetinib treatment in BRAF V600 mutated melanoma Yan, Yibing McArthur, Grant Hamid, Omid Puzanov, Igor Gonzalez, Rene Gajewski, Thomas Wang, Yulei Wongchenko, Matthew Choong, Nicholas Ribas, Antoni J Transl Med Oral Presentation BioMed Central 2014-05-06 /pmc/articles/PMC4108918/ http://dx.doi.org/10.1186/1479-5876-12-S1-O12 Text en Copyright © 2014 Yan et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Oral Presentation Yan, Yibing McArthur, Grant Hamid, Omid Puzanov, Igor Gonzalez, Rene Gajewski, Thomas Wang, Yulei Wongchenko, Matthew Choong, Nicholas Ribas, Antoni Biomarker analysis of on-treatment and at progression biopsies from BRIM7 - a phase 1B trial of combined vemurafenib and cobimetinib treatment in BRAF V600 mutated melanoma |
| title | Biomarker analysis of on-treatment and at progression biopsies from BRIM7 - a phase 1B trial of combined vemurafenib and cobimetinib treatment in BRAF V600 mutated melanoma |
| title_full | Biomarker analysis of on-treatment and at progression biopsies from BRIM7 - a phase 1B trial of combined vemurafenib and cobimetinib treatment in BRAF V600 mutated melanoma |
| title_fullStr | Biomarker analysis of on-treatment and at progression biopsies from BRIM7 - a phase 1B trial of combined vemurafenib and cobimetinib treatment in BRAF V600 mutated melanoma |
| title_full_unstemmed | Biomarker analysis of on-treatment and at progression biopsies from BRIM7 - a phase 1B trial of combined vemurafenib and cobimetinib treatment in BRAF V600 mutated melanoma |
| title_short | Biomarker analysis of on-treatment and at progression biopsies from BRIM7 - a phase 1B trial of combined vemurafenib and cobimetinib treatment in BRAF V600 mutated melanoma |
| title_sort | biomarker analysis of on-treatment and at progression biopsies from brim7 - a phase 1b trial of combined vemurafenib and cobimetinib treatment in braf v600 mutated melanoma |
| topic | Oral Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4108918/ http://dx.doi.org/10.1186/1479-5876-12-S1-O12 |
| work_keys_str_mv | AT yanyibing biomarkeranalysisofontreatmentandatprogressionbiopsiesfrombrim7aphase1btrialofcombinedvemurafenibandcobimetinibtreatmentinbrafv600mutatedmelanoma AT mcarthurgrant biomarkeranalysisofontreatmentandatprogressionbiopsiesfrombrim7aphase1btrialofcombinedvemurafenibandcobimetinibtreatmentinbrafv600mutatedmelanoma AT hamidomid biomarkeranalysisofontreatmentandatprogressionbiopsiesfrombrim7aphase1btrialofcombinedvemurafenibandcobimetinibtreatmentinbrafv600mutatedmelanoma AT puzanovigor biomarkeranalysisofontreatmentandatprogressionbiopsiesfrombrim7aphase1btrialofcombinedvemurafenibandcobimetinibtreatmentinbrafv600mutatedmelanoma AT gonzalezrene biomarkeranalysisofontreatmentandatprogressionbiopsiesfrombrim7aphase1btrialofcombinedvemurafenibandcobimetinibtreatmentinbrafv600mutatedmelanoma AT gajewskithomas biomarkeranalysisofontreatmentandatprogressionbiopsiesfrombrim7aphase1btrialofcombinedvemurafenibandcobimetinibtreatmentinbrafv600mutatedmelanoma AT wangyulei biomarkeranalysisofontreatmentandatprogressionbiopsiesfrombrim7aphase1btrialofcombinedvemurafenibandcobimetinibtreatmentinbrafv600mutatedmelanoma AT wongchenkomatthew biomarkeranalysisofontreatmentandatprogressionbiopsiesfrombrim7aphase1btrialofcombinedvemurafenibandcobimetinibtreatmentinbrafv600mutatedmelanoma AT choongnicholas biomarkeranalysisofontreatmentandatprogressionbiopsiesfrombrim7aphase1btrialofcombinedvemurafenibandcobimetinibtreatmentinbrafv600mutatedmelanoma AT ribasantoni biomarkeranalysisofontreatmentandatprogressionbiopsiesfrombrim7aphase1btrialofcombinedvemurafenibandcobimetinibtreatmentinbrafv600mutatedmelanoma |